Dynavax Technologies  (NASDAQ:DVAX) shares inched up today following the release of the company's Q3 results. For the quarter, revenues came in at $2.93 million, up modestly from the $2.87 million in the same period the previous year. The firm managed to narrow its loss during the period, posting a $15.7 million ($0.09 per diluted share) shortfall against Q3 2012's loss of $17.8 million ($0.10).

Last month, the company concurrently floated common and preferred stock issues. The estimated gross proceeds from both were pegged at $132 million. At the end of its Q3, Dynavax's cash, cash equivalents, and marketable securities stood at $76.5 million.

In trading today, the company's stock crept upwards by 0.5%, or $0.01, to $1.12.

Fool contributor Eric Volkman has no position in Dynavax Technologies. Nor does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.